# Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers

> **NCT03175211** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 456906
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03175211
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-30
- **Primary completion:** 2018-02-19
- **Final completion:** 2018-02-19
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03175211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03175211, "Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03175211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*